Chinubhai Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 35 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 152.25%
(FY 2022)
- Profit 1146.60%
(FY 2022)
- Ebitda 362.31%
(FY 2022)
- Net Worth 34.56%
(FY 2022)
- Total Assets 31.37%
(FY 2022)
About Chinubhai Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kailas Shah, Ashish Shah, Chinmay Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231GJ1989PTC012957
- Company No.
012957
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Chinubhai Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kailas Shah  | Director | 01-Nov-1989 | Current |
| Ashish Shah | Director | 31-Mar-2009 | Current |
| Chinmay Shah | Director | 24-Jun-2009 | Current |
| Maulik Shah | Director | 12-Apr-2022 | Current |
Financial Performance of Chinubhai Pharma.
Chinubhai Pharma Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 152.25% increase. The company also saw a substantial improvement in profitability, with a 1146.6% increase in profit. The company's net worth Soared by an impressive increase of 34.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chinubhai Pharma?
In 2022, Chinubhai Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Navil Laboratories Pvt LtdActive 32 years 5 monthsAshish Shah, Chinmay Shah and 1 more are mutual person
Chanchalba Gordhandas Shah Khavadwala Charitable & Welfare FoundationActive 9 years 1 monthAshish Shah, Chinmay Shah and 1 more are mutual person
- Chandanbala Pranlal Botadara Welfare FoundationActive 9 years 11 months
Chinmay Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chinubhai Pharma?
Unlock and access historical data on people associated with Chinubhai Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chinubhai Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chinubhai Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
